Ab124921

Ribociclib (S7440) and Infigratinib (S2183) were purchased from Selleck Chemicals and were dissolved in 21% Captisol and 30% PEG300 solution (vehicle) for oral administration. Antibodies against FGFR1 (#9740), FGFR3 (#4574), FGFR4 (#8562), AKT (#9272), Rb (#9313), cyclin B1 (#4138), Cdc25C (#4688), Cyclin D1 (#2978), Cyclin E2 (#4132), survivin (#2803), Sox9 (#82630), cleaved PARP (#5625), β catenin (#8480), α‐tubulin (#2144) and phosphorylation‐specific antibodies against AKT Ser473 (#9271), FRS2‐α Tyr439 (#3861), Rb Ser807/811 (#9308), Histone 3 Ser10 (#9701), Cdc2 Tyr15 (#9111) and Erk1/2 Thr202/Tyr204 (#4370) were obtained from Cell Signaling Technology. Antibodies against CYP3A4 (ab124921) and HNF4‐α (ab201460) were from Abcam. The antibodies against FGFR2 (#sc‐122), Erk1/2 (#sc‐94), FRS2‐α (#sc‐17841), GAPDH (sc‐166545) and Cdk2 Thr14/Tyr15 (#sc‐28435‐R) were from Santa Cruz Biotechnology Inc. Anti‐mouse CD31 antibody (#2502) was from BioLegend. Anti‐albumin (#SAB4200711; clone HAS‐11) antibody was purchased from Sigma‐Aldrich.

Protein levels in lysed LO-2 cells and homogenized liver cells were determined by western blotting as previously described [9 (link)]. Cell samples were blotted with 1 : 1,000-diluted rabbit anti-CYP1A2 and 1 : 5,000- diluted GAPDH polyclonal antibodies (Proteintech Group Inc., Rosemont, IL, USA), CYP2C9 polyclonal antibody (1 : 1, 000, Abcam, ab4236), rabbit anti-CYP2C19 polyclonal antibody (1 : 1, 000, Abcam, ab137015), rabbit anti-CYP3A4 polyclonal antibody (1 : 1, 000, Abcam, ab124921), and mouse anti-hypoxia induced factor-1α monoclonal antibody (1 : 1000, Novus Biologicals, Littleton, CO, USA). Liver samples were blotted with 1 : 1000-diluted goat anti-CYP1A1+CYP1A2 (ab4227) polyclonal and 1 : 5,000-diluted mouse anti-GAPDH (ab9482) monoclonal antibodies (Abcam).